Lupin Q1 Results 2024, Significant Growth with Revenue of ₹41,676.3 million

For the quarter ending June 30, 2024, Lupin, a global pharmaceutical company, reported its financial performance. The company saw significant revenue growth, with total revenue from operations reaching ₹41,676.3 million. This is an increase from ₹34,956.4 million in the same quarter last year. Lupin's other income was ₹382.2 million, which added to its total income of ₹42,058.5 million for the quarter.

The company's expenses for this period were ₹31,229.3 million. These included costs such as raw materials, employee benefits, and other operating costs. After deducting these expenses from the total income, Lupin's profit before tax was ₹10,829.2 million. The company incurred a tax expense of ₹1,937.4 million, which led to a net profit of ₹8,891.8 million for the quarter.

Lupin's other comprehensive income was positive at ₹13.4 million. This means the total comprehensive income, after considering other factors, was ₹8,823.6 million. The company’s earnings per share were ₹8.43 for basic shares and ₹8.40 for diluted shares.

Source: Here

Lupin Q1 Results 2024

Lupin's financial results for the first quarter of 2024 showed a solid performance. The company achieved substantial revenue growth and maintained strong profitability. The increase in revenue was driven by higher sales and operational income.

Despite the rise in expenses, Lupin managed to record a significant profit before tax. The company's net profit and comprehensive income were both robust, reflecting positive financial health for the beginning of the fiscal year.

Lupin Q1 2024 Results:

Lupin Limited 

Lupin Limited is a big pharmaceutical company based in Mumbai, India. It was started in 1968 by Desh Bandhu Gupta, who used money borrowed from his wife to begin the company. Lupin began by making folic acid and iron tablets for a government health program. Later, it became well-known for making anti-tuberculosis (TB) drugs. At one point, Lupin was the largest maker of TB drugs in the world.

Lupin's main focus is on making medicines for various health issues like heart problems, infections, diabetes, asthma, and TB. The company also produces over-the-counter drugs, vaccines, contact lenses, and products for animal health.

In 2015, Lupin bought two companies, Gavis Pharmaceuticals and Novel Laboratories, for $880 million. In 2023, it agreed to buy a French company called Medisol. The company has a strong research and development team with over 1,400 scientists working on new drugs and improving existing ones.